Search

Your search keyword '"Melanie A. Thompson"' showing total 116 results

Search Constraints

Start Over You searched for: Author "Melanie A. Thompson" Remove constraint Author: "Melanie A. Thompson"
116 results on '"Melanie A. Thompson"'

Search Results

1. Ending the HIV Epidemic in Metropolitan Atlanta: a mixed‐methods study to support the local HIV/AIDS response

2. Assessing statin effects on cardiovascular pathways in HIV using a novel proteomics approach: Analysis of data from INTREPID, a randomized controlled trialResearch in context

4. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel

5. Fixed Duration Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone Quadruplet for Newly Diagnosed Multiple Myeloma - MRD Negativity and Survival Outcomes

6. Core Elements of a National COVID-19 Strategy: Lessons Learned from the US National HIV/AIDS Strategy

7. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

8. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials

9. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial

10. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

11. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel

12. Acute haemoptysis, fever and abdominal pain in an adolescent from northern Australia

13. Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America

14. Differential Plasma Protein Regulation and Statin Effects in Human Immunodeficiency Virus (HIV)-Infected and Non-HIV-Infected Patients Utilizing a Proteomics Approach

15. Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials

16. The return of PRO 140, a CCR5-directed mAb

17. Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial

18. The first 90: the gateway to prevention and care: opening slowly, but not for all

19. Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib

20. A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus

21. Assessing Statin Effects on Cardiovascular Pathways in HIV Using a Novel Proteomics Approach: Analysis of Data from Intrepid, a Randomized Controlled Trial

22. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

24. 1288. Bone Safety Outcomes with F/TAF vs. F/TDF for PrEP in the DISCOVER Trial

25. Sexual Risk Behavior Among HIV-Uninfected Men Who Have Sex With Men Participating in a Tenofovir Preexposure Prophylaxis Randomized Trial in the United States

26. The State of Engagement in HIV Care in the United States: From Cascade to Continuum to Control

27. DNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emergent Virus

28. Systematic review of the diagnosis of scabies in therapeutic trials

29. Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults

30. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

31. Antiretroviral Treatment of Adult HIV Infection 2010 Recommendations of the International AIDS Society-USA Panel

32. Antiviral Activity of Single‐Dose PRO 140, a CCR5 Monoclonal Antibody, in HIV‐Infected Adults

33. Seven-Year Efficacy of a Lopinavir/Ritonavir-Based Regimen in Antiretroviral—Naïve HIV-1-Infected Patients

34. Antiretroviral treatment of adult HIV infection - 2008 recommendations of the International AIDS Society USA panel

35. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis

36. Whole‐Blood Interleukin‐18 Level during Early HIV‐1 Infection Is Associated with Reduced CXCR4 Coreceptor Expression and Interferon‐γ Levels

37. Safety and Efficacy of TAF Versus TDF Single-Tablet Regimen in HIV-1 Treatment-Naive Black and Non-Black Patients Through Week 48

38. Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects

39. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation

40. Factors That Complicate the Treatment of Tuberculosis in HIV-Infected Patients

41. Effects of Growth Hormone on Abnormal Visceral Adipose Tissue Accumulation and Dyslipidemia in HIV-Infected Patients

42. Betamethasone associated changes in umbilical artery flow velocity waveforms in multiple pregnancies with umbilical artery absent end diastolic flow

43. Impact of an Educational Program on Efficacy and Adherence With a Twice-Daily Lamivudine/Zidovudine/Abacavir Regimen in Underrepresented HIV-Infected Patients

44. Differences in Prescription of Antiretroviral Therapy in a Large Cohort of HIV-Infected Patients

45. Rotavirus Cerebellitis: New Aspects to an Old Foe?

46. Once‐Daily Quadruple‐Drug Therapy with Adefovir Dipivoxil, Lamivudine, Didanosine, and Efavirenz in Treatment‐Naive Human Immunodeficiency Virus Type 1–Infected Patients

47. A Controlled Phase Ii Trial Assessing Three Doses of Enfuvirtide (T-20) in Combination with Abacavir, Amprenavir, Ritonavir and Efavirenz in Non-Nucleoside Reverse Transcriptase Inhibitor-Naive HIV-Infected Adults

48. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy

49. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy

50. Efficacy Testing of Recombinant Human Immunodeficiency Virus (HIV) gp160 as a Therapeutic Vaccine in Early‐Stage HIV‐1–Infected Volunteers

Catalog

Books, media, physical & digital resources